NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia

Phase 2

Completed

Conditions: Essential Thrombocythemia
Polycythemia Vera
Primary Myelofibrosis

Interventions: Drug: tipifarnib
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT00047190

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Tanespimycin, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: gemcitabine hydrochloride
Drug: tanespimycin
Drug: cisplatin
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 78

Registration Number: NCT00047047

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Flavopiridol Plus Radiation Therapy Followed By Gemcitabine Hydrochloride in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer

Phase 1

Completed

Conditions: Adenocarcinoma of the Pancreas
Recurrent Pancreatic Cancer
Stage II Pancreatic Cancer
Stage III Pancreatic Cancer
Stage IV Pancreatic Cancer

Interventions: Drug: alvocidib
Drug: gemcitabine hydrochloride
Radiation: 3-dimensional conformal radiation therapy
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 46

Registration Number: NCT00047307

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Pyrazoloacridine Plus Carboplatin in Treating Patients With Recurrent Glioma

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

Interventions: Drug: carboplatin
Drug: pyrazoloacridine

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00005976

Locations: 🇺🇸
CentraCare Health Plaza, Saint Cloud, Minnesota, United States
🇺🇸
Medcenter One Health System, Bismarck, North Dakota, United States
🇺🇸
Altru Cancer Center, Grand Forks, North Dakota, United States

and more 20 locations

Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Nodal Marginal Zone B-cell Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Small Lymphocytic Lymphoma
Splenic Marginal Zone Lymphoma

Interventions: Biological: rituximab
Biological: recombinant interleukin-12
Other: laboratory biomarker analysis
Other: questionnaire administration
Procedure: quality-of-life assessment

First Posted Date: 2003-01-27

Last Posted Date: 2013-08-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 99

Registration Number: NCT00026182

Locations: 🇺🇸
North Central Cancer Treatment Group, Rochester, Minnesota, United States

Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2

Completed

Conditions: Fallopian Tube Cancer
Primary Peritoneal Cavity Cancer
Recurrent Ovarian Epithelial Cancer
Stage III Ovarian Epithelial Cancer
Stage IV Ovarian Epithelial Cancer

Interventions: Drug: bryostatin 1
Drug: cisplatin
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-08-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 32

Registration Number: NCT00006942

Locations: 🇺🇸
City of Hope, Duarte, California, United States

Lobradimil and Carboplatin in Treating Children With Brain Tumors

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2003-01-27

Last Posted Date: 2013-08-16

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00019422

Locations: 🇺🇸
Emory University Hospital - Atlanta, Atlanta, Georgia, United States
🇺🇸
Naval Medical Center, Portsmouth, Portsmouth, Virginia, United States
🇺🇸
Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States

and more 232 locations

Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors

Phase 2

Completed

Conditions: Adult Giant Cell Glioblastoma
Adult Glioblastoma
Adult Gliosarcoma

Interventions: Drug: erlotinib hydrochloride
Radiation: 3-dimensional conformal radiation therapy
Drug: temozolomide

First Posted Date: 2003-01-27

Last Posted Date: 2013-08-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 171

Registration Number: NCT00039494

Locations: 🇺🇸
Graham Hospital Association, Canton, Illinois, United States
🇺🇸
Mcdonough District Hospital, Macomb, Illinois, United States
🇺🇸
Siouxland Regional Cancer Center, Sioux City, Iowa, United States

and more 136 locations

Thalidomide Plus Interferon Alfa in Treating Patients With Progressive Liver Cancer That Cannot be Surgically Removed

Phase 2

Completed

Conditions: Liver Cancer

Interventions: Biological: recombinant interferon alfa
Drug: thalidomide

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 38

Registration Number: NCT00006006

Locations: 🇺🇸
NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States
🇺🇸
Mount Sinai School of Medicine, New York, New York, United States

Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma

Phase 3

Completed

Conditions: Stage I Multiple Myeloma
Stage II Multiple Myeloma
Stage III Multiple Myeloma

Interventions: Drug: vincristine sulfate
Drug: carmustine
Drug: melphalan
Drug: cyclophosphamide
Drug: prednisone
Other: laboratory biomarker analysis
Biological: recombinant interferon alfa-2b

First Posted Date: 2003-01-27

Last Posted Date: 2013-05-31

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 312

Registration Number: NCT00002556

Locations: 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy